ERBB2 and neoplasm: In the context of HER2-negative lesions (Figure 2B), Al18F-NOTA-HER2-BCH exhibited lower uptake in tumor sites, contrasting with high uptake observed with 18F-FDG, aligning with the low HER2 expression determined by IHC.